Gigabecquerel to Megabecquerel

The patient swallows a capsule containing 1–7 GBq of I-131. The thyroid gland concentrates iodine from the bloodstream — it cannot tell radioactive iodine from stable iodine — so the isotope accumulates right where you want it. I-131 emits beta particles with a range of about 2 mm in tissue, which destroy thyroid cells from the inside while sparing nearby structures. The gamma rays it also emits are used for imaging to verify uptake. Within weeks the targeted tissue is dead, no scalpel required.

At 3–7 GBq, a freshly treated thyroid cancer patient is a walking radiation source. They emit gamma rays and excrete I-131 in sweat, saliva, and urine for days. Regulations typically require isolation until the retained activity drops below 1.1 GBq or the dose rate at 1 meter falls below 25 µSv/hr. That usually means 2–5 days of sleeping alone, using a dedicated bathroom, and avoiding prolonged close contact — especially with children and pregnant women, who are more radiation-sensitive.

Brachytherapy places a sealed radioactive source directly inside or next to a tumor — "brachy" is Greek for "short distance." High-dose-rate (HDR) sources of iridium-192 at 100–370 GBq deliver an intense, highly localized dose in minutes. The inverse-square law means tissue just centimeters away receives dramatically less radiation. This precision is why brachytherapy can treat cervical, prostate, and breast cancers with fewer side effects than external beam radiation alone.

Industrial radiography sources (1–20 GBq of Ir-192 or Se-75) live inside heavy shielded containers called "cameras" or "projectors" made of depleted uranium or tungsten. The source is only pushed out through a guide tube during an exposure, and the area is roped off with radiation monitors. Strict transport regulations, tamper-proof locks, and regular inventory audits apply. When sources decay below useful activity, they are returned to the manufacturer. The IAEA maintains a database of lost or orphaned sources — the ones that slip through the system occasionally cause severe accidents.

Diagnostic procedures use just enough activity to produce a readable image — typically 50–800 MBq (0.05–0.8 GBq). The goal is information, not tissue destruction. Therapeutic procedures aim to kill cells, so they use 10 to 100 times more: 1–7 GBq for thyroid ablation, 100–370 GBq for HDR brachytherapy sources. The line between them is roughly 1 GBq. Below that, you are taking a picture; above it, you are prescribing a lethal dose to a very specific target.

Diagnostic imaging doses fall neatly in the MBq range — a PET scan uses 185–370 MBq, a bone scan 500–800 MBq. Using becquerels would mean writing hundreds of millions; using gigabecquerels would mean awkward decimals like 0.37 GBq. MBq is the Goldilocks unit for the hospital pharmacy: large enough to avoid scientific notation, small enough to express a single patient dose as a tidy number on a syringe label.

That depends entirely on the isotope. Technetium-99m, the workhorse of diagnostic imaging, has a 6-hour half-life — so a 740 MBq injection drops to 370 MBq in 6 hours, 185 MBq in 12, and becomes negligible within 2 days. Fluorine-18 (used in PET) has a 110-minute half-life and is essentially gone in a day. Iodine-131 (used in therapy) lingers for about 8 days per half-life. Hospitals choose isotopes partly based on how fast they want the activity to vanish.

Most diagnostic isotopes (Tc-99m, F-18) have half-lives under a day, so hospitals simply store waste in shielded bins and let it decay. After 10 half-lives — about 3 days for Tc-99m — the activity is down to less than 0.1% of the original and can be disposed of as normal clinical waste. Longer-lived therapeutic isotopes like I-131 require weeks of decay storage. The vast majority of nuclear medicine waste is never shipped to a radioactive disposal site; it just sits in a locked closet until physics solves the problem.

A patient injected with 370 MBq of F-18 for a PET scan emits gamma rays at a dose rate of roughly 5–6 µSv/hr at one meter. That means sitting next to them for two hours gives you about 10–12 µSv — less than a chest X-ray. Staff handle dozens of patients daily so they follow time-and-distance protocols, but for family members the exposure from a single visit is trivially small. The activity halves every 110 minutes, so by evening the patient is barely distinguishable from background.

Molybdenum-99, which decays into the technetium-99m used in 30+ million scans per year worldwide, can only be produced in a handful of aging research reactors. It has a 66-hour half-life so it cannot be stockpiled — you have to make it, ship it, and use it within days. When a reactor goes down for maintenance (as happened in 2009 when both the Canadian NRU and Dutch HFR shut down simultaneously), hospitals worldwide face scan cancellations within a week. New production methods using particle accelerators and LEU targets are slowly diversifying supply.